Chmielowski, B., Milhem, M. M., Sacco, J. J., Bowles, T. L., Tsai, K. K., In, G. K., … Middleton, M. R. (2023). Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Chmielowski, Bartosz, Mohammed M. Milhem, Joseph J. Sacco, Tawnya Lynn Bowles, Katy K. Tsai, Gino Kim In, Eva Munoz-Couselo, et al. “Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Chmielowski B, Milhem MM, Sacco JJ, Bowles TL, Tsai KK, In GK, et al. Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Chmielowski, Bartosz, et al. “Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Chmielowski B, Milhem MM, Sacco JJ, Bowles TL, Tsai KK, In GK, Munoz-Couselo E, Vanderwalde AM, Chesney JA, Michels J, Samson A, Beasley G, Schadendorf D, Mahmoud F, Wong MKK, Wise-Draper TM, Zhu J, Bommareddy P, Hou JW, Middleton MR. Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study. JOURNAL OF CLINICAL ONCOLOGY. 2023.